Clinical trial
Phase I Study of the Administration of T Lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma
NCT03602157 is registered in ClinicalTrials.gov with UNC Lineberger Comprehensive Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I Study of the Administration of T Lymphocytes Co-Expressing the CD30 Chimeric Antigen Receptor (CAR) and CCR4 for Relapsed/Refractory CD30+ Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- October 29, 2018
- Completion date
- November 4, 2039
- Enrollment
- 43 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cutaneous anaplastic large cell lymphoma, cutaneous lymphoma, cutaneous t cell lymphoma, gray zone lymphoma, immune system diseases, immunoproliferative disorders, lymphatic diseases, lymphoma, lymphomatoid papulosis, lymphoproliferative disorders, mycosis fungoides, neoplasms, sezary syndrome